STOCK TITAN

Can-Fite Biopharma Ltd - CANF STOCK NEWS

Welcome to our dedicated news page for Can-Fite Biopharma (Ticker: CANF), a resource for investors and traders seeking the latest updates and insights on Can-Fite Biopharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Can-Fite Biopharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Can-Fite Biopharma's position in the market.

Rhea-AI Summary
Can-Fite BioPharma Ltd. expands its out licensing transaction with Ewopharma AG to include the pancreatic cancer indication for Piclidenoson and Namodenoson. Ewopharma AG paid Can-Fite an upfront payment of US$2.25 million with up to an additional US$40.45 million, plus 17.5% royalties on net sales. The distribution agreement allows Ewopharma AG to market and sell the drugs in CEE countries and Switzerland. Can-Fite is pleased with the expansion and considers it an important transaction for the company's penetration into Ewopharma's territory.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
none
-
Rhea-AI Summary
Can-Fite BioPharma Ltd. announces the publication of a phase 3 clinical trial for piclidenoson in plaque psoriasis in the Journal of the European Academy of Dermatology and Venereology. The study met its primary endpoint, showing significant improvement in Psoriasis Area and Severity Index (PASI) scores. The drug demonstrated excellent safety and tolerability and is currently being evaluated in a pivotal Phase III study approved by the FDA and EMA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.14%
Tags
clinical trial
-
Rhea-AI Summary
Can-Fite BioPharma Ltd. (CANF) reports new data on Namodenoson's potential as an anti-obesity drug, highlighting its ability to reduce body weight and inhibit fat levels. The global obesity treatment market is projected to reach $100 billion by 2030, making Namodenoson a potential contender in this lucrative market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
none
Rhea-AI Summary
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) received a positive response from the FDA on the Pediatric Study Plan for the treatment of children suffering from psoriasis with Piclidenoson. The plan aims at registration of Piclidenoson with both the FDA and the EMA for the treatment of plaque psoriasis. There is a high market need for a safe and efficacious drug for the treatment of children who suffer from psoriasis. Can-Fite believes the inclusion of children in one or both of the Phase 3 studies significantly broadens any future market launch potential of the drug.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.48%
Tags
none
-
Rhea-AI Summary
XYZ Pharmaceuticals (XYZ) Announces Clinical Trial to Enroll Patients for New Drug Study
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.92%
Tags
clinical trial
-
Rhea-AI Summary
Can-Fite BioPharma Ltd. (CANF) announced a patient in their Phase II study remains cancer-free 6.9 years after starting treatment with Namodenoson. The company reported financial results, clinical milestones, and drug development advancements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.29%
Tags
earnings
Rhea-AI Summary
Can-Fite BioPharma Ltd. (CANF) announced a definitive agreement for the exercise of outstanding warrants to purchase up to 1,963,637 American Depositary Shares (ADSs) at a reduced exercise price of $1.53 per share. The closing of the offering is expected to occur soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.47%
Tags
none
-
Rhea-AI Summary
Can-Fite BioPharma Ltd. (CANF) announces a patient treated with namodenoson in the Phase II Liver Cancer Study has achieved a complete response and 6.9 years overall survival. The FDA and EMA have approved a pivotal Phase III clinical study, enrolling patients in Israel, Europe, and the US. Namodenoson has Orphan Drug and Fast Track Status for the treatment of HCC. The market for HCC treatments is estimated to reach $3.8 billion by 2027 for the G8 countries.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.47%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.93%
Tags
none
Rhea-AI Summary
Can-Fite BioPharma announced that the scientific journal Biomolecules published an article on the drug candidate namodenoson, highlighting its inhibition of pancreatic carcinoma growth and its mechanism of action. The company is developing an exploratory Phase II study to evaluate the safety and efficacy of namodenoson in treating patients with pancreatic carcinoma who failed first-line therapy. Namodenoson is also being evaluated in a Phase III study approved by the FDA and EMA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.15%
Tags
none
Can-Fite Biopharma Ltd

NYSE:CANF

CANF Rankings

CANF Stock Data

12.70M
1.22B
4.89%
0.19%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Israel
P O Box 7537

About CANF

can fite biopharma (canfy) is a biotechnology company based out of 10 bareket street, פ"ת, israel.